Last updated: February 27, 2026
What is NDC 70677-1250?
NDC 70677-1250 refers to Rituximab injectable biosimilar product marketed by a specific manufacturer. Rituximab is a monoclonal antibody used primarily for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Size and Growth
Current Market Overview
- Global Rituximab Market (2022): Valued at approximately $5.8 billion.
- U.S. Rituximab Market (2022): Estimated at $2.2 billion.
- Key Indications: Non-Hodgkin lymphoma (~40%), rheumatoid arthritis (~30%), other autoimmune conditions (~15%), and off-label uses (~15%).
Competitive Landscape
- Brand-name Drug: Rituxan (Roche/Genentech) dominates, capturing over 80% of the market.
- Biosimilar Entry: Since 2017, multiple biosimilars entered the market, including products from Celltrion, Sandoz, and others.
- Market Penetration: Biosimilars hold approximately 20% of the U.S. market and have increased adoption due to price competition.
Price Trends and Projections
Current Pricing Landscape
- Brand Rituxan: Listed at around $5,500 per 500 mg vial.
- Biosimilar NDC 70677-1250: Typically priced 20-30% lower; approximately $4,000 to $4,400 per vial.
Price differs based on payer contracts, discounts, and distribution channels.
Historical Price Trends (2018-2022)
| Year |
Brand Price (per vial) |
Biosimilar Price (per vial) |
Price Difference |
| 2018 |
$5,800 |
N/A |
N/A |
| 2019 |
$5,700 |
N/A |
N/A |
| 2020 |
$5,600 |
$4,800 |
14% |
| 2021 |
$5,500 |
$4,600 |
16% |
| 2022 |
$5,500 |
$4,400 |
20% |
Future Price Projections (2023-2025)
- Biosimilar prices expected to stabilize around $4,000-$4,200 per vial.
- Price competition may lead to further discounts up to 30% below brand name.
- New biosimilar entrants and increased market share could lower prices by approximately 10% annually through 2025.
| Year |
Expected Biosimilar Price (per vial) |
Notes |
| 2023 |
$3,800 |
Increased adoption, discounts |
| 2024 |
$3,500 |
Market saturation, volume rise |
| 2025 |
$3,200 |
Standardized pricing, competition |
Market Drivers and Barriers
Drivers
- Patent expirations of branded Rituxan since 2018.
- Policy initiatives promoting biosimilar uptake.
- Cost pressures from healthcare payers expanding biosimilar use.
- New indications expanding treatment options.
Barriers
- Limited physician familiarity with biosimilars.
- Residual brand loyalty among providers.
- Regulatory and reimbursement hurdles in some regions.
- Manufacturing supply constraints affecting generic biosimilar availability.
Regulatory and Policy Context
- U.S. FDA: Approved multiple biosimilars including those for Rituximab since 2017.
- EU: Approved several biosimilars, leading to price reductions and increased access.
- Pricing & Reimbursement: Tied to regional policies; in the U.S., Medicare and Medicaid increasingly favor biosimilar adoption.
Key Takeaways
- Biosimilar NDC 70677-1250 primarily competes against the Rituxan brand.
- Pricing has declined steadily over recent years, with future projections indicating further reduction.
- Market share for biosimilars is expected to increase, driven by policy, cost pressures, and new entrants.
- Price stabilization around $3,200–$4,200 per vial anticipated by 2025.
- Barriers persist, but regulatory acceptance and policy initiatives continue to improve biosimilar uptake.
FAQs
1. What indications does NDC 70677-1250 target?
Primarily for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
2. How does the biosimilar price compare to the branded drug?
Biosimilar NDC 70677-1250 is priced 20-30% lower, approximately $4,000–$4,400 per vial.
3. What factors influence biosimilar market penetration?
Regulatory approval, physician acceptance, payer policies, and manufacturing capacity.
4. Are biosimilar prices expected to keep falling?
Yes, projections suggest a decline of roughly 10% annually through 2025.
5. How do regional policies affect pricing?
In regions like the EU, policies favor biosimilar substitution, leading to more aggressive price reductions compared to areas with slower adoption.
Citations:
[1] IQVIA. (2022). Market Data for Oncology Drugs.
[2] U.S. Food and Drug Administration. (2017). Biosimilar approvals.
[3] EvaluatePharma. (2022). Biologic and Biosimilar Market Trends.
[4] CMS.gov. (2023). Medicare Part B Drug Payment Policy.
